Biotechnology in Belgium
Published: August 2013 · Publisher: MarketLine
Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The Belgian biotechnology market had total revenues of $6.2bn in 2012, representing a compound annual growth rate (CAGR) of 7.9% between 2008 and 2012.
*While Belgium represents less than 3.0% of the European population, it has approximately 140 biotech companies, which accounts for 7.0% of all European biotech firms, and employs around 10,000 people.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $8.5bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Belgium
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Belgium
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Belgium biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Belgium economy
Key Questions Answered
What was the size of the Belgium biotechnology market by value in 2012?
What will be the size of the Belgium biotechnology market in 2017?
What factors are affecting the strength of competition in the Belgium biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up Belgium's biotechnology market?
Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The Belgian biotechnology market had total revenues of $6.2bn in 2012, representing a compound annual growth rate (CAGR) of 7.9% between 2008 and 2012.
*While Belgium represents less than 3.0% of the European population, it has approximately 140 biotech companies, which accounts for 7.0% of all European biotech firms, and employs around 10,000 people.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $8.5bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Belgium
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Belgium
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Belgium biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Belgium economy
Key Questions Answered
What was the size of the Belgium biotechnology market by value in 2012?
What will be the size of the Belgium biotechnology market in 2017?
What factors are affecting the strength of competition in the Belgium biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up Belgium's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
#N/A
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Novartis AG 19
Sanofi 23
ThromboGenics NV 26
AstraZeneca PLC 29
Macroeconomic Indicators 32
Country Data 32
Appendix 34
Methodology 34
Industry associations 35
Related research 35
LIST OF TABLES
Table 1: Belgium biotechnology market value: $ billion, 2008–12 8
Table 2: Belgium biotechnology market category segmentation: $ billion, 2012 9
Table 3: Belgium biotechnology market geography segmentation: $ billion, 2012 10
Table 4: Belgium biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Novartis AG: key facts 19
Table 6: Novartis AG: key financials ($) 20
Table 7: Novartis AG: key financial ratios 21
Table 8: Sanofi: key facts 23
Table 9: Sanofi: key financials ($) 24
Table 10: Sanofi: key financials (€) 24
Table 11: Sanofi: key financial ratios 24
Table 12: ThromboGenics NV: key facts 26
Table 13: ThromboGenics NV: key financials ($) 27
Table 14: ThromboGenics NV: key financials (€) 27
Table 15: ThromboGenics NV: key financial ratios 27
Table 16: AstraZeneca PLC: key facts 29
Table 17: AstraZeneca PLC: key financials ($) 30
Table 18: AstraZeneca PLC: key financial ratios 30
Table 19: Belgium size of population (million), 2008–12 32
Table 20: Belgium gdp (constant 2000 prices, $ billion), 2008–12 32
Table 21: Belgium gdp (current prices, $ billion), 2008–12 32
Table 22: Belgium inflation, 2008–12 33
Table 23: Belgium consumer price index (absolute), 2008–12 33
Table 24: Belgium exchange rate, 2008–12 33
LIST OF FIGURES
Figure 1: Belgium biotechnology market value: $ billion, 2008–12 8
Figure 2: Belgium biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: Belgium biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: Belgium biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in Belgium, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in Belgium, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in Belgium, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Belgium, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Belgium, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in Belgium, 2012 18
Figure 11: Novartis AG: revenues & profitability 21
Figure 12: Novartis AG: assets & liabilities 22
Figure 13: Sanofi: revenues & profitability 25
Figure 14: Sanofi: assets & liabilities 25
Figure 15: ThromboGenics NV: assets & liabilities 28
Figure 16: AstraZeneca PLC: revenues & profitability 31
Figure 17: AstraZeneca PLC: assets & liabilities 31
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Novartis AG 19
Sanofi 23
ThromboGenics NV 26
AstraZeneca PLC 29
Macroeconomic Indicators 32
Country Data 32
Appendix 34
Methodology 34
Industry associations 35
Related research 35
LIST OF TABLES
Table 1: Belgium biotechnology market value: $ billion, 2008–12 8
Table 2: Belgium biotechnology market category segmentation: $ billion, 2012 9
Table 3: Belgium biotechnology market geography segmentation: $ billion, 2012 10
Table 4: Belgium biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Novartis AG: key facts 19
Table 6: Novartis AG: key financials ($) 20
Table 7: Novartis AG: key financial ratios 21
Table 8: Sanofi: key facts 23
Table 9: Sanofi: key financials ($) 24
Table 10: Sanofi: key financials (€) 24
Table 11: Sanofi: key financial ratios 24
Table 12: ThromboGenics NV: key facts 26
Table 13: ThromboGenics NV: key financials ($) 27
Table 14: ThromboGenics NV: key financials (€) 27
Table 15: ThromboGenics NV: key financial ratios 27
Table 16: AstraZeneca PLC: key facts 29
Table 17: AstraZeneca PLC: key financials ($) 30
Table 18: AstraZeneca PLC: key financial ratios 30
Table 19: Belgium size of population (million), 2008–12 32
Table 20: Belgium gdp (constant 2000 prices, $ billion), 2008–12 32
Table 21: Belgium gdp (current prices, $ billion), 2008–12 32
Table 22: Belgium inflation, 2008–12 33
Table 23: Belgium consumer price index (absolute), 2008–12 33
Table 24: Belgium exchange rate, 2008–12 33
LIST OF FIGURES
Figure 1: Belgium biotechnology market value: $ billion, 2008–12 8
Figure 2: Belgium biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: Belgium biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: Belgium biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in Belgium, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in Belgium, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in Belgium, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Belgium, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Belgium, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in Belgium, 2012 18
Figure 11: Novartis AG: revenues & profitability 21
Figure 12: Novartis AG: assets & liabilities 22
Figure 13: Sanofi: revenues & profitability 25
Figure 14: Sanofi: assets & liabilities 25
Figure 15: ThromboGenics NV: assets & liabilities 28
Figure 16: AstraZeneca PLC: revenues & profitability 31
Figure 17: AstraZeneca PLC: assets & liabilities 31
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.